Our previous study showed that intrathecal (i.t.) injection of platelet-activating factor (PAF) induced tactile allodynia, suggesting that spinal PAF is a mediator of neuropathic pain. The present study further examined the spinal molecules participating in PAFinduced tactile allodynia in mice. I.t. injection of L-arginine, NO donor (5-amino-3-morpholinyl-1,2,3-oxadiazolium (SIN-1) or 3,3-bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene (NOC-18)) or cGMP analog (8-(4-chlorophenylthio)-guanosine 3 0 ,5 0 -cyclic monophosphate; pCPT-cGMP) induced tactile allodynia. PAF-and glutamate-but not SIN-1-or pCPT-cGMP-induced tactile allodynia was blocked by an NO synthase inhibitor. NO scavengers and guanylate cyclase inhibitors protected mice against the induction of allodynia by PAF, glutamate and SIN-1, but not by pCPT-cGMP. cGMP-dependent protein kinase (PKG) inhibitors blocked the allodynia induced by PAF, glutamate, SIN-1 and pCPT-cGMP. To identify signalling molecules through which PKG induces allodynia, glycine receptor a3 (GlyR a3) was knocked down by spinal transfection of siRNA for GlyR a3. A significant reduction of GlyR a3 expression in the spinal superficial layers of mice treated with GlyR a3 siRNA was confirmed by immunohistochemical and Western blotting analyses. Functional targeting of GlyR a3 was suggested by the loss of PGE 2 -induced thermal hyperalgesia and the enhancement of allodynia induced by bicuculline, a GABA A receptor antagonist in mice after GlyR a3 siRNA treatment. pCPT-cGMP, PAF, glutamate and SIN-1 all failed to induce allodynia after the knockdown of GlyR a3. These results suggest that the glutamate-NO-cGMP-PKG pathway in the spinal cord may be involved in the mechanism of PAF-induced tactile allodynia, and GlyR a3 could be a target molecule through which PKG induces allodynia.
Introduction
Platelet-activating factor (PAF) is a lipid mediator of the inflammatory response. PAF is elevated in cerebrospinal fluid in association with various diseases accompanied by abnormal pain sensation, such as spinal cord injury [32] and relapsing-remitting multiple sclerosis [4] , and contributes to robust inflammatory responses in the acute phase and secondary injury in spinal cord injury [13, 23] and in experimental allergic encephalomyelitis [29] . Although PAF is believed to be a potent edematous mediator, but not a pain mediator, in peripheral tissues, we recently demonstrated that intrathecal injection of PAF produced potent tactile allodynia and thermal hyperalgesia in mice [37] . Thus, PAF may be a mediator of noxious signalling in the spinal cord in some cases of neuronal injury. 
